Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL284632 | 1.00 | ALDH1A1 (0.50) | ALDH1A1LMNATSHRTDP1MAPT | |
| SCHEMBL14129694 | 1.00 | ALDH1A1 (0.50) | ALDH1A1LMNATSHRTDP1MAPT | |
| SCHEMBL13969438 | 1.00 | ALDH1A1 (0.50) | ALDH1A1LMNATSHRTDP1MAPT | |
| SCHEMBL30392575 | 1.00 | ALDH1A1 (0.50) | ALDH1A1LMNATSHRTDP1MAPT | |
| SCHEMBL6702143 | 1.00 | ALDH1A1 (0.50) | ALDH1A1LMNATSHRTDP1MAPT | |
| SCHEMBL14754592 | 1.00 | ALDH1A1 (0.50) | ALDH1A1LMNATSHRTDP1MAPT | |
| SCHEMBL19171465 | 1.00 | ALDH1A1 (0.50) | ALDH1A1LMNATSHRTDP1MAPT | |
| SCHEMBL1014010 | 1.00 | ALDH1A1 (0.50) | ALDH1A1LMNATSHRTDP1MAPT | |
| SCHEMBL12807993 | 0.95 | ALDH1A1 (0.46) | ALDH1A1LMNATSHRTDP1MAPT | |
| SCHEMBL10070710 | 0.95 | ALDH1A1 (0.46) | ALDH1A1LMNATSHRTDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7235590-B2 | Use of treosulfan and derivatives thereof for treating multiple sclerosis | MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH (DE) | 2007-06-26 | — | — | US | disclosed |
| US-20060041015-A1 | Use of treosulfan and derivaties thereof for treating multiple sclerosis | MEDAC GESELLSCHAFT FUR KLINISCHE SPEZIALPRAPARATE MBH (DE) | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041015-A1 | Use of treosulfan and derivaties thereof for treating multiple sclerosis | TST, TXNRD3, TXN | ALDH1A1 450/4885LMNA 4451/4885TSHR 2001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.